7 Best Peptides for POTS & Dysautonomia

What to Know Before Choosing a Peptide for POTS & Dysautonomia

POTS and dysautonomia sit in a genuinely complicated corner of the peptide conversation. Standard front-line treatments, things like midodrine, beta-blockers, and ivabradine, help many people but leave a significant number still searching for what else might move the needle. That search has led a growing community of patients, functional medicine practitioners, and researchers toward peptides.

Every compound in this guide earned its place by one criterion: people are using it or actively discussing using it for POTS and dysautonomia. That includes FDA-approved drugs used off-label, telemedicine-prescribed compounds, research-only peptides, and compounds whose evidence base is almost entirely community-reported. Evidence strength is described honestly inside each entry rather than used as a filter for inclusion. A compound with only anecdotal support belongs here, with that stated plainly, just as much as one with published clinical data.

The entries are ordered by how prominently each compound appears in the research and in real-world use by the POTS community, not as a ranking of one being better or safer than another for any particular person. The right choice depends heavily on your subtype, whether you have MCAS overlap, whether connective tissue involvement is part of your picture, and what else you are already managing. That personalized layer is what the MyPeptidePal app handles; this guide gives you the honest field of options first.

One note before the entries: people with POTS are widely described by practitioners as exquisitely sensitive to new substances, particularly those with concurrent mast cell activation syndrome, or MCAS. A starting principle that runs through nearly every functional medicine protocol for this population is start low, go slow. Keep that in mind as you read.

1. Octreotide: The Only Peptide with Off-Label Clinical Evidence for POTS

Octreotide is a synthetic analog of somatostatin, a naturally occurring regulatory peptide that broadly inhibits hormone and peptide secretion throughout the body. It is FDA-approved for acromegaly and carcinoid syndrome, which makes it a real pharmaceutical available via prescription rather than a research chemical. That status matters in the POTS context because it is the only peptide compound with meaningful published human data specifically relevant to the condition.

The mechanism that makes octreotide relevant to POTS is fairly direct. One of the central problems in many POTS subtypes is that blood pools in the splanchnic circulation, the dense vascular network surrounding the gut, when a person moves from lying down to standing. This pooling reduces the blood available to return to the heart, which then races to compensate. Octreotide causes vasoconstriction in that splanchnic bed, tightening those vessels and reducing the pooling effect. Small studies have found that this translates to a measurable reduction in orthostatic tachycardia and improved standing tolerance.

It is not widely used as a first-line POTS therapy, partly because of its administration requirements and partly because its effect on multiple hormone systems means it is typically reserved for people whose symptoms are not controlled by simpler interventions. But among the peptides people discuss for this goal, octreotide stands apart for having an established, physician-supervised off-label evidence base rather than relying solely on mechanistic reasoning or anecdote. If a prescribing clinician experienced in dysautonomia is part of your team, this is the compound to raise first.

2. Thymosin Alpha-1: The Immune Stabilizer That Comes First

Thymosin Alpha-1 is an immunomodulatory peptide derived from the thymus gland. It plays a regulatory role in immune function, and its effects on mast cell activity are the primary reason it surfaces repeatedly in POTS-specific protocols.

Here is why that matters: a substantial proportion of people with POTS also have mast cell activation syndrome. MCAS causes the immune system to react inappropriately to triggers that would not affect most people, and introducing new compounds, including other peptides, can set off that reactivity. Functional medicine practitioners who work with dysautonomia populations consistently place Thymosin Alpha-1 first in their peptide sequencing for exactly this reason. It is described as having the lowest flare risk among the compounds commonly used in this space, and its job is to create a more stable immunological foundation before anything else is added.

The safety record behind Thymosin Alpha-1 is more substantial than most compounds in this category. It has been studied across more than 11,000 patients in over 30 trials, primarily in Asia where it has been used as an approved immunotherapy, and the adverse event profile from that body of data consists mainly of minor injection-site reactions. That history does not translate directly to a POTS indication, since no published randomized controlled trial has evaluated Thymosin Alpha-1 specifically for POTS or dysautonomia. What exists is a rationale grounded in its immune-regulatory mechanism, practitioner protocols from functional medicine clinicians, and community-reported use. Many people in the POTS community who have worked with these protocols describe starting here, waiting for stability, and then layering additional compounds.

It is worth noting that Thymosin Alpha-1 is among the peptides moved to the FDA Category 2 Bulk Drug Substance list in 2024 and 2025, which restricts compounding pharmacies from preparing it for patients. Access for US-based patients has changed meaningfully as a result of that reclassification.

3. Thymosin Beta-4 / TB-500: For Connective Tissue and Systemic Repair

Thymosin Beta-4 is a naturally occurring peptide involved in tissue regeneration, wound healing, and the maintenance of connective tissue. TB-500 is the shortened synthetic version most commonly used in practice, corresponding to the actin-binding fragment of the full molecule. In the POTS community, it comes up most often in the context of the significant overlap between POTS and hypermobile Ehlers-Danlos syndrome.

EDS is a connective tissue disorder that affects the structural integrity of joints, fascia, and blood vessel walls. People with hEDS and POTS frequently experience microtrauma from the constant small movements their hypermobile joints allow, and that accumulating tissue stress is thought to contribute to the systemic inflammation and autonomic instability that characterizes their presentation. Thymosin Beta-4 addresses this angle through its effects on tissue repair and its ability to reduce systemic inflammation. Users in this subgroup report that it helps with what they describe as the connective tissue component of their symptoms, including fascial resilience and recovery from physical activity.

There is no published clinical trial data for Thymosin Beta-4 in POTS or dysautonomia. What has been reported comes from community protocols and functional medicine practitioners who describe it as a useful adjunct for the EDS/POTS overlap specifically. The consistent caution in those protocols is that TB-500 should not be introduced until Thymosin Alpha-1 has been running long enough to stabilize immune and mast cell function. Like Thymosin Alpha-1, it was reclassified under the FDA Category 2 Bulk Drug Substance restrictions, affecting compounding access in the United States.

4. SS-31 / Elamipretide: For Mitochondrial Function and Brain Fog

SS-31, also known as elamipretide, is a mitochondria-targeting peptide that works by binding to cardiolipin, a phospholipid that sits in the inner mitochondrial membrane and plays a central role in the membrane's structural integrity and its ability to generate energy. When cardiolipin is damaged or dysfunctional, the mitochondria produce less energy and release more oxidative stress. SS-31 stabilizes cardiolipin and helps restore mitochondrial efficiency.

The reason this matters for POTS and dysautonomia is that mitochondrial dysfunction is increasingly recognized as a component of the condition, particularly in post-COVID presentations and in people with chronic fatigue as a prominent feature. Users who have reported on SS-31 in the context of dysautonomia describe improvements in brain fog and cognitive clarity, a reduction in the sense of being unable to accomplish tasks, and better energy levels overall. A description that recurs in community accounts is feeling mentally clearer, with the cognitive capacity that had been lost to dysautonomia becoming more accessible again.

SS-31 is notable in this group for a specific regulatory reason: elamipretide received FDA approval in 2025 for Barth syndrome, a rare mitochondrial disease affecting cardiac and skeletal muscle function. That approval is for a different condition and does not extend to POTS, so any use for dysautonomia remains off-label and experimental. The approval does, however, provide a body of safety data that most compounds in this category simply do not have. No published randomized controlled trial has evaluated SS-31 for POTS specifically as of 2026; the evidence for this use is drawn from user-reported experience and the mechanistic reasoning above.

5. VIP: For Vascular Tone and Neuroinflammation

Vasoactive Intestinal Peptide, commonly called VIP, is an endogenous neuropeptide produced throughout the nervous system and gut. It acts as a potent vasodilator, relaxing blood vessel walls and reducing vascular resistance, and it carries well-established anti-inflammatory effects on nervous system tissue. In healthy physiology, VIP helps regulate a range of autonomic functions including gut motility, immune tone, and blood vessel behavior.

In POTS and MCAS populations, VIP levels are often found to be low. The functional medicine rationale for supplementing it is that this deficiency may contribute to the dysregulated vascular tone and nervous system inflammation that characterize dysautonomia. Some telemedicine practitioners offer VIP as a nasal spray formulation, and this route has become the most commonly discussed approach in that clinical context. Users who report benefit describe reductions in dizziness and in the heart rate acceleration that accompanies position changes.

The honest picture on VIP is that its use for POTS rests primarily on mechanistic rationale and clinical anecdote. No published randomized controlled trials have evaluated VIP for POTS as of 2026. What exists is a plausible biological case grounded in VIP's known vasodilatory and anti-inflammatory actions, observations from functional medicine practitioners who note low VIP levels in their POTS patients, and user-reported experiences that are generally positive but uncontrolled. VIP does not have an FDA-approved indication for POTS, and compounded VIP preparations have been subject to the same FDA compounding restrictions that have affected several other peptides in this space since 2024.

6. BPC-157: For Gut and Nerve Repair, With Important Caveats

BPC-157, which stands for Body Protection Compound-157, is a synthetic pentadecapeptide derived from a protein found in gastric juice. It is best known in peptide communities for its effects on tissue healing, gut mucosal repair, and peripheral nerve function. Among the mechanisms tied to its repair effects is angiogenesis, the growth of new blood vessels into damaged tissue.

The rationale for BPC-157 in POTS and dysautonomia comes from multiple angles. Gastrointestinal dysfunction is common in dysautonomia, affecting gut motility, absorption, and mucosal integrity, and BPC-157's role in gut healing addresses that component directly. Users who have reported benefit for dysautonomia specifically describe improvements in peripheral nerve function, better sleep quality, and in some cases what they call a complete resolution of POTS symptoms. There are also community accounts of BPC-157 being used as part of combination protocols where its vascular and nerve-repair properties are the primary target.

What must be stated plainly is that this compound carries a serious caution for this specific population. BPC-157 can worsen symptoms in people with MCAS, which is prevalent in POTS. Functional medicine practitioners who work in this space consistently recommend that BPC-157 not be introduced until immune and mast cell function has been stabilized, typically through a prior course of Thymosin Alpha-1. Some users with POTS have reported intensified symptoms rather than improvement. Individual variability here is significant and real.

On the regulatory side, the FDA moved BPC-157 to its Category 2 Bulk Drug Substance list in 2024 and 2025, which bars compounding pharmacies from preparing it for patients and means that obtaining it through legal pharmaceutical channels in the United States is no longer straightforward. No clinical trial data has been published for BPC-157 in POTS specifically as of 2026. Its place in this guide reflects the frequency with which it appears in community discussions and practitioner protocols for this goal, with its evidence base described accurately: experiential rather than clinical, and accompanied by a population-specific risk that warrants real caution.

7. MOTS-c: For Cellular Energy and Autonomic Stability

MOTS-c is a mitochondrial-derived peptide, meaning it is encoded by the mitochondrial genome rather than the nuclear genome, which makes it unusual among the compounds in this space. Its primary effects involve mitochondrial biogenesis, the process by which cells build new mitochondria, along with glucose regulation and cellular stress resilience. It has attracted attention in longevity and metabolic research for its ability to improve how cells produce and use energy.

In the POTS context, MOTS-c is used because of the mitochondrial dysfunction component that appears in post-COVID dysautonomia and in chronic fatigue presentations more broadly. The reasoning is that if the autonomic nervous system's ability to regulate blood pressure, heart rate, and vascular tone is partly compromised by poor cellular energy production, then a compound that improves mitochondrial efficiency at the cellular level could contribute to greater autonomic stability. There is also a glucose regulation angle worth noting: elevated GIP, a gut-derived peptide that acts as a splanchnic vasodilator, has been observed in POTS patients after eating and may drive postprandial worsening of orthostatic tachycardia. MOTS-c's effects on glucose handling could be relevant to that dynamic.

No human clinical trial data has been published for MOTS-c in POTS or dysautonomia as of 2026. Its presence in protocols for this goal is drawn from functional medicine practitioners who take a mitochondrial approach to dysautonomia and from the mechanistic reasoning above. Community reports are limited but present. The evidence here is at the rationale-driven, early-adoption stage rather than the clinically validated one, and that distinction is worth carrying clearly into any conversation with a practitioner.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides FDA-approved for POTS?

One compound on this list, octreotide, is FDA-approved but for a different condition, acromegaly and carcinoid syndrome, and its use for POTS is off-label. SS-31 received FDA approval in 2025 for Barth syndrome, a separate mitochondrial disease, and that approval does not extend to dysautonomia. None of the other compounds on this list carry an FDA approval for any indication related to POTS.

Is it safe to use peptides when you have MCAS alongside POTS?

MCAS is one of the most important factors to account for when considering peptides for POTS, because people with mast cell involvement can react strongly to substances that would be well-tolerated in other populations. Practitioners experienced with this population consistently recommend starting with an immune-stabilizing compound before introducing anything else, and adopting a strict start-low, go-slow approach throughout. BPC-157 in particular carries a recognized risk of worsening symptoms in people with active MCAS. Working with a physician who understands both MCAS and dysautonomia is essential before starting any peptide protocol.

Do these peptides address the root cause of POTS, or mostly the symptoms?

It depends on the compound and the subtype. Mitochondrial peptides like SS-31 and MOTS-c aim to improve cellular function that may be a contributing factor. Octreotide primarily addresses a downstream symptom, the splanchnic pooling effect, rather than whatever triggered the autonomic dysfunction. VIP supplementation targets a potential deficiency in the signaling pathway. Most people with POTS are managing a combination of contributing causes rather than a single one, which is part of why practitioner guidance on sequencing and compound selection matters considerably.

How long do people typically use these compounds before seeing any change?

Timelines vary considerably by compound and by individual. Community protocols for SS-31 often describe multi-month courses before a clear picture emerges. User accounts of BPC-157 for nerve and gut repair describe effects appearing over weeks to months. One framing that recurs across multiple community reports is that the early benefit felt like a small but compounding advantage rather than a dramatic overnight shift. In a population as sensitive as POTS patients tend to be, gradual titration means gradual feedback as well.

What changed for compounded peptides after the 2024 to 2025 FDA reclassifications?

Several peptides in this guide, including Thymosin Alpha-1, Thymosin Beta-4, and BPC-157, were moved to the FDA Category 2 Bulk Drug Substance list in 2024 and 2025. That reclassification bars compounding pharmacies in the United States from preparing these compounds for patients, representing a significant change in legal availability for people who had been accessing them through that channel. The regulatory landscape continues to evolve, and confirming current access with a knowledgeable practitioner before building a protocol around any specific compound is worth doing.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for POTS and dysautonomia in one place.